business

Kiran Mazumdar-Shaw Aims to Enhance Access to Essential Medications

21 Ağustos 2026Bloomberg

Kiran Mazumdar-Shaw, often referred to as India's 'Queen of Biotech', has transformed Biocon from a small garage operation into a multibillion-dollar enterprise, becoming a key player in the production of insulin and biosimilars. As she prepares to pass on her legacy, she shares insights into her journey as a pionee…
Mazumdar-Shaw emphasizes her commitment to making life-saving therapies accessible and discusses the necessary steps India must take to adapt to an AI-driven future.
Kiran Mazumdar-Shaw's rise in the biotech industry coincides with India's growing emphasis on healthcare innovation and accessibility. As the global demand for affordable insulin and biosimilars increases, her company, Biocon, stands at the forefront of this movement.
Mazumdar-Shaw's journey exemplifies the potential of female leadership in the biotech sector, particularly in a country like India where such narratives are still emerging. Her focus on accessibility to life-saving drugs highlights a critical gap in healthcare that needs addressing, especially in developing nations.

NewsAI özeti

This article is based on an interview and reflects the views of Kiran Mazumdar-Shaw and Bloomberg.